BeyondSpring, Inc. - Ordinary Shares (BYSI): Price and Financial Metrics


BeyondSpring, Inc. - Ordinary Shares (BYSI): $0.60

-0.01 (-1.05%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

BYSI POWR Grades

  • Growth is the dimension where BYSI ranks best; there it ranks ahead of 75.37% of US stocks.
  • BYSI's strongest trending metric is Stability; it's been moving up over the last 145 days.
  • BYSI ranks lowest in Momentum; there it ranks in the 4th percentile.

BYSI Stock Summary

  • BYSI has a higher market value than just 8.83% of US stocks; more precisely, its current market capitalization is $28,417,121.
  • With a price/sales ratio of 21.03, BEYONDSPRING INC has a higher such ratio than 94.34% of stocks in our set.
  • Revenue growth over the past 12 months for BEYONDSPRING INC comes in at 650.56%, a number that bests 98.38% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to BEYONDSPRING INC are PTN, ANGN, MTP, ALBO, and XBIO.
  • Visit BYSI's SEC page to see the company's official filings. To visit the company's web site, go to www.beyondspringpharma.com.

BYSI Valuation Summary

  • In comparison to the median Healthcare stock, BYSI's price/sales ratio is 1063.16% higher, now standing at 22.1.
  • BYSI's EV/EBIT ratio has moved up 47.3 over the prior 69 months.

Below are key valuation metrics over time for BYSI.

Stock Date P/S P/B P/E EV/EBIT
BYSI 2022-11-01 22.1 1.1 -0.5 0.1
BYSI 2022-10-31 21.5 1.1 -0.5 0.1
BYSI 2022-10-28 23.0 1.2 -0.5 0.1
BYSI 2022-10-27 22.6 1.1 -0.5 0.1
BYSI 2022-10-26 24.5 1.2 -0.5 0.1
BYSI 2022-10-25 24.5 1.2 -0.5 0.1

BYSI's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • BYSI has a Quality Grade of C, ranking ahead of 27.77% of graded US stocks.
  • BYSI's asset turnover comes in at 0.01 -- ranking 391st of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows BYSI's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.010 1 -20.655
2021-03-31 0.007 1 85.551
2020-12-31 0.003 1 -1154.275
2020-09-30 0.000 NA -49.454
2020-06-30 0.000 NA -21.489
2020-03-31 0.000 NA -2964.190

BYSI Price Target

For more insight on analysts targets of BYSI, see our BYSI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $61.17 Average Broker Recommendation 1.21 (Strong Buy)

BYSI Stock Price Chart Interactive Chart >

Price chart for BYSI

BYSI Price/Volume Stats

Current price $0.60 52-week high $15.40
Prev. close $0.60 52-week low $0.58
Day low $0.59 Volume 59,000
Day high $0.62 Avg. volume 309,052
50-day MA $0.86 Dividend yield N/A
200-day MA $1.53 Market Cap 23.21M

BeyondSpring, Inc. - Ordinary Shares (BYSI) Company Bio


BeyondSpring is a global clinical stage biopharmaceutical company developing innovative immuno-oncology cancer therapies. The co is advancing its lead asset, Plinabulin, into a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer and a Phase 2/3 clinical trial in the prevention of chemotherapy-induced Neutropenia.


BYSI Latest News Stream


Event/Time News Detail
Loading, please wait...

BYSI Latest Social Stream


Loading social stream, please wait...

View Full BYSI Social Stream

Latest BYSI News From Around the Web

Below are the latest news stories about BEYONDSPRING INC that investors may wish to consider to help them evaluate BYSI as an investment opportunity.

BeyondSpring's Lead Cancer Drug Protects Bone Marrow Stem Cells Within 24 Hours

BeyondSpring Inc (NASDAQ: BYSI) announced data from a poster presentation at the ESMO Congress 2022, including a new analysis from the Phase 2/3 PROTECTIVE-1 and PROTECTIVE-2 trials of plinabulin. Plinabulin, the company's lead asset, is a selective immunomodulating microtubule-binding agent, a potent antigen-presenting cell (APC) inducer being developed as an anticancer agent. Related: BeyondSpring Presents New Data From Lead Asset On Neutropenia In Multiple Myeloma Patients. The data provides

Yahoo | September 13, 2022

BeyondSpring Presents New Clinical Evidence of Plinabulin Protection of Granulocyte-Monocyte Progenitor Stem Cells for the Prevention of Chemotherapy-Induced Neutropenia at the ESMO Congress 2022

Plinabulin rapidly (within 24 hours) mitigates chemotherapy-induced myelosuppression by protecting bone marrow granulocyte-monocyte progenitor (GMP) stem cellsNEW YORK, Sept. 13, 2022 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a clinical stage global biopharmaceutical company focused on developing innovative cancer therapies to improve clinical outcomes for patients who have a high unmet medical need, today announced data from a poster presentation at

Yahoo | September 13, 2022

BeyondSpring Presents New Data From Lead Asset On Neutropenia In Multiple Myeloma Patients

BeyondSpring Inc (NASDAQ: BYSI) announced new data from a study evaluating the reduction in neutropenia burden with lead asset plinabulin in combination with pegfilgrastim in multiple myeloma. The study included patients who have undergone autologous hematopoietic stem cell transplantation (AHCT) and have received a high dose of melphalan, a type of chemotherapy. Median white blood count on Day 0, 1 and 2 was 7.6 (3.6 – 9.8), 5 (3.2 – 13.6) and 18.7 (5.1-59.1) x 10^9 cells/L, respectively. Relat

Yahoo | August 29, 2022

BeyondSpring Presents New Data for the Use of Plinabulin and Pegfilgrastim to Decrease Neutropenia Burden in Peri-Transplant Multiple Myeloma Patients at the 19th International Myeloma Society Annual Meeting

Plinabulin was well tolerated and only one out of the 10 patients enrolled had non-engraftment related neutropenic fevers or febrile neutropenia (FN) with the plinabulin/pegfilgrastim combinationNEW YORK, Aug. 29, 2022 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a clinical stage global biopharmaceutical company focused on developing innovative cancer therapies to improve clinical outcomes for patients who have a high unmet medical need, today announced

Yahoo | August 29, 2022

Codexis (CDXS) Surges 9.7%: Is This an Indication of Further Gains?

Codexis (CDXS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Yahoo | June 27, 2022

Read More 'BYSI' Stories Here

BYSI Price Returns

1-mo -23.36%
3-mo -54.89%
6-mo N/A
1-year -95.82%
3-year -95.39%
5-year -98.15%
YTD -86.75%
2021 -62.87%
2020 -21.29%
2019 -17.33%
2018 -35.52%
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7292 seconds.